Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

Date
ASCO congratulates the eleven practices that prioritized the quality of care they provide by achieving the Quality Oncology Practice Initiative (QOPI®) Certification in the second half of 2020. These practices have shown that they are committed to providing the highest-quality oncology care to their patients, communities, and contemporaries. 
On February 22, 2021, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression (Tumor Proportion Score [TPS] > 50%) as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations.
ASCO is currently tracking 57 telemedicine bills across the states and working with State Societies and other medical specialty groups on the ground to weigh in on this emerging issue.  On January 27, Maryland HB 123/SB 3 were heard in their chambers’ respective health care committees.
ASCO recently posted the following guidelines:
ASCO believes that the best cancer care starts with the best cancer information. Our patient education website, Cancer.Net, gives patients and caregivers the expertise and resources from ASCO in plain, easy-to-understand language so they may make informed health care decisions. Refer your patients to Cancer.Net, where they will find information on more than 120 types of cancer and cancer-related syndromes, survivorship, treatment options, supportive care, caregiving, and much more.
The American Society of Clinical Oncology (ASCO) issued a new position statement strongly opposing the use of copay accumulator programs and copay maximizer programs for individuals with cancer. The statement also makes recommendations to protect patients from the potential harms of such programs.
In the days and weeks leading up to President Biden’s inauguration, the Department of Health and Human Services (HHS)—under the prior administration—issued a number of rules and regulations that affect cancer care delivery. Many of those rules and regulations are now subject to review by the new administration and/or Congress.
ASCO's Clinical Practice Committee’s Advanced Practice Providers (APP) Task Force has developed a guide to assist in the onboarding planning and process of APP in oncology. The purpose of this document is to provide a framework for the onboarding process and to provide a simple supplement to support a comprehensive integration of new APP team members into team-based oncology, practice at the top of license, and with support of physician and APP mentors. This resource is meant to be a supplement to existing onboarding processes and practices.